Biosimilar in lymphoma treatment
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021.
| Autor principal: | |
|---|---|
| Outros Autores: | |
| Formato: | Tese |
| Idioma: | English |
| Publicado em: |
Brac University
2021
|
| Assuntos: | |
| Acesso em linha: | http://hdl.handle.net/10361/15533 |
| id |
10361-15533 |
|---|---|
| record_format |
dspace |
| spelling |
10361-155332021-10-25T21:01:22Z Biosimilar in lymphoma treatment Tanisha, Mehrin Haque Kabir, Eva Rahman Department of Pharmacy, Brac University Biosimilar Cancer Lymphoma Rituximab Cancer--Treatment This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021. Cataloged from PDF version of thesis report. Includes bibliographical references (pages 61-72). We are living in an era where the number of ageing population is increasing, as well as the demand for treating chronic conditions like cancer, cardiovascular disease, diabetes, etc. Considering the different types of cancer, lymphoma is one of the leading causes of death, with an estimated 259,793 deaths (2.6%) in 2020. Focusing on treatment with biosimilars, this review study aims to address the Rituximab biosimilars in lymphoma care. The patent of Rituximab has expired recently, resulting in concerns for patients with regard to accessibility particularly in countries with limited funding. These challenges stimulated the development and manufacturing of Rituximab biosimilars. The review also discusses the potential advantages and impacts of Rituximab biosimilars in lymphoma patients. Mehrin Haque Tanisha B. Pharmacy 2021-10-25T05:47:31Z 2021-10-25T05:47:31Z 2021 2021-04 Thesis ID 17146020 http://hdl.handle.net/10361/15533 en Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 72 pages application/pdf Brac University |
| institution |
Brac University |
| collection |
Institutional Repository |
| language |
English |
| topic |
Biosimilar Cancer Lymphoma Rituximab Cancer--Treatment |
| spellingShingle |
Biosimilar Cancer Lymphoma Rituximab Cancer--Treatment Tanisha, Mehrin Haque Biosimilar in lymphoma treatment |
| description |
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021. |
| author2 |
Kabir, Eva Rahman |
| author_facet |
Kabir, Eva Rahman Tanisha, Mehrin Haque |
| format |
Thesis |
| author |
Tanisha, Mehrin Haque |
| author_sort |
Tanisha, Mehrin Haque |
| title |
Biosimilar in lymphoma treatment |
| title_short |
Biosimilar in lymphoma treatment |
| title_full |
Biosimilar in lymphoma treatment |
| title_fullStr |
Biosimilar in lymphoma treatment |
| title_full_unstemmed |
Biosimilar in lymphoma treatment |
| title_sort |
biosimilar in lymphoma treatment |
| publisher |
Brac University |
| publishDate |
2021 |
| url |
http://hdl.handle.net/10361/15533 |
| work_keys_str_mv |
AT tanishamehrinhaque biosimilarinlymphomatreatment |
| _version_ |
1814308619313741824 |